Business Description
Immunic Inc. is a US and Germany-based biotech company founded in 2016 that creates oral treatments for chronic inflammatory and autoimmune conditions. Its most advanced drug candidate, IMU-838, is currently in Phase 2 and Phase 3 trials targeting multiple sclerosis and ulcerative colitis. The company is also working on IMU-856, which enters Phase 2 trials to help restore gut barrier function in patients with conditions such as celiac disease and irritable bowel syndrome, as well as IMU-381, an early-stage treatment for gastrointestinal diseases.
